Journey Medical Corp DERM
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Journey Medical Corp (DERM) is a healthcare company listed in the US with a market value of about $122M. In the twelve months to September 30, 2026 it had revenue of $70M and net income of -$5M, a net margin of -7.3%.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 7% a year, a 5-year average ROIC of -30%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 36% below the current price.
About Journey Medical
Journey Medical is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $45M in 2020 to $62M in 2025, growth of about 6.8% a year. It was profitable in 1 of the last 6 years in our data. Its share count rose by 40% over three years (dilution for shareholders). It spends 1% of revenue on research and development.
Score: 0.2 / 5
Checks passed
- Revenue growth above 10% last year
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $70M | $62M | $56M | $79M | $74M | $63M | $45M |
| Net income | -$5M | -$11M | -$15M | -$4M | -$30M | -$44M | $5M |
| Free cash flow | — | — | -$24M | $240000 | -$34M | — | — |
| EPS (diluted) | $-0.18 | $-0.47 | $-0.72 | $-0.21 | $-1.69 | $-4.32 | $0.49 |
| Net margin | -7.3% | -18.5% | -26.1% | -4.9% | -40.2% | -69.7% | 11.9% |
| ROIC | — | -11.3% | -23.9% | -4.7% | -48.4% | -64.1% | 55.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $13.33, 208% above the current price; targets range from $13.00 to $14.00; the consensus rating is “Strong buy”; expected EPS is $-0.07 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Journey Medical stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 36% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Journey Medical pay a dividend?
Not currently.
Is Journey Medical a good stock to buy?
We do not give buy or sell advice. Journey Medical scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.